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Abstract 
The synthesis of poly(2-oxazoline)s has been known since the 1960s. In the last two decades they 
have risen in popularity thanks to improvements in their synthesis and the realization of their potential 
in the biomedical field due to their non-fouling or ‘stealth’ properties, stimuli responsiveness and 
tailorable properties. Even though the bulk of the research to date has been on linear forms of the 
polymer, they are also of interest for forming network structures due to the relatively easy 
introduction of reactive functional groups during synthesis that can be crosslinked under a variety of 
conditions. In this opinion article, we briefly review the history of poly(2-oxazoline)s and examine the 
in vivo data on soluble poly(2-oxazoline)s to date in an effort to predict how hydrogels may perform 
as implantable materials. This is followed by an overview of the most recent hydrogel synthesis 
methods, emerging applications and concludes with a section on the future directions predicted for 
this fascinating and versatile class of polymer. 
 
1. Introduction 
Synthetic hydrogels have become an invaluable tool to a number of emerging biomaterial applications 
requiring high water content gels. These include drug delivery, tissue engineering and subclasses of 
these, such as 3D cell culture, and more recently, biofabrication. Concomitant to the advances of these 
fields, there has been an increase in the variety of crosslinking chemistry and sophistication contained 
within the underlying hydrogels since the first synthetic hydrogel, poly(2-hydroxyethyl methacrylate), 
was described by Wichterle and Lim in 1960.[1] Despite almost 60 years’ worth of research into 
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synthetic hydrogels, the majority of products translated to market can be classified into just a few 
categories, namely contact lenses, hygiene products and wound dressings. Undoubtedly more 
hydrogels will enter the market in the foreseeable future in the form of drug delivery and tissue 
engineering devices as the technologies mature.[2]  
For many of the established bulk hydrogel applications, e.g. hygiene products and contact lenses, the 
polymerization mechanism has been around low-cost traditional free-radical polymerizations. More 
recently though, the focus has been around developing and exploiting low energy crosslinking 
chemistry (light activated,[3] ‘click’ reactions,[4] enzyme mediated,[5] thermogelation[6]) of polymeric 
precursors so that biological components can be included (e.g. peptides,[7] growth factors,[8] cells[9]). 
Furthermore, the use of controlled and living polymerization methods for the preparation of the 
hydrogel precursors provides control over the spacing of crosslinks leading to near-ideal network 
structures.[10] A key development towards advanced hydrogels was the work of Hubbell and Lutolf 
who prepared polyethylene glycol (PEG) hydrogels based on enzymatic crosslinking with cell-
instructive degradation points by using cleavable peptide substrates as crosslinkers.[5] This evolution 
of the hydrogel from a passive material into an active material with tissue-like characteristics[11-15] has 
reinvigorated the field. 
One of the most successful and intensively studied synthetic polymers for the preparation of 
hydrogels is PEG. Soluble PEG (i.e. non-crosslinked) has been ubiquitous in biology laboratories for 
precipitation of biomolecules and cell fusion since the mid-1950s.[16] In his commentary, ‘The Origin 
of pegnology’, Frank Davis describes the beginnings of his pioneering work into PEGylation of 
proteins in the late 1960s for reducing immunogenicity following intravenous injection of liposomes 
and therapeutic proteins. What set PEG apart from other polymers of the time was that it was 
available as well-defined monomethoxy PEG with a single hydroxyl-functionalized terminus, 
prepared by living anionic polymerization. This long history of using PEG in biological applications 
together with the availability of well-defined structures (now including star-architecture PEGs) and its 
well-known ‘stealth’/ non-fouling behaviour have made it a popular choice as a hydrogel material for 
biomedical applications. 
In recent years, poly(2-alkyl/aryl-2-oxazoline)s (PAOx) (Figure 1) are increasingly being proposed as 
an alternative to PEG.[17-19] Much of the focus on PAOx has been on the ease of synthesis as well as 
on self-assembling non-crosslinked materials. Nonetheless, there is also interest in using PAOx for 
hydrogels based on the additional functionality available through the side-chains allowing for high 
degrees of conjugation or crosslinking. Perhaps the earliest example of a PAOx hydrogel was from 
Litt who presented at a 2012 symposium on PAOx his early work in the 1960s on using thiol-ene 
photochemistry to crosslink functional PAOx,[20] although there is no peer reviewed account of this 
work. Later in the 1980s and early 1990s, Chujo and Saegusa published a large body of innovative 
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work on PAOx hydrogels based on covalent, dynamic covalent and supramolecular crosslinking.[21-32] 
These reports appeared, however, before the field of biomaterials became widespread and so their 
materials were not used with biological systems. 
 
Figure 1: General scheme for the cationic ring opening polymerization of 2-oxazolines and the 
structure of the resulting poly(2-alkyl/aryl-2-oxazoline)s. 
To understand the evolution of PAOx as a hydrogel material it is useful to look at the timelines in 
which it has been developed. PAOx was first synthesized experimentally in the 1960s by four 
independent groups[33-36] and later on industrial scale in the 1980s.[37] PAOx is pseudo-peptidic in 
structure (the amide is on the side-chain, not the backbone as with peptides) that can be prepared with 
a variety of 2-substituted-2-oxazoline monomers leading to a range of physical properties such that it 
can be considered a class of polymers.[38] The cationic ring opening polymerization (CROP) of 2-
alkyl/aryl-2-oxazoline monomers is used to form the polymer but the process is susceptible to chain 
transfer and other modes of uncontrolled termination, especially when aiming at higher molar mass 
polymers and in presence of nucleophilic impurities, such as water. This meant that for a long time it 
was not thought of as a polymer for which low polydispersity could be achieved for higher molar 
mass polymers. We can speculate that Frank Davis would have been aware of PAOx during his 
library searches, but disregarded it since at the time PAOx was only available as an ill-defined 
polymer. Thus, PAOx remained as a curiosity to just a few research groups struggling to gain more 
widespread attention, until recently. 
The renewed interest in PAOx can be traced to the development of methods for accelerating reaction 
rates for the CROP of 2-oxazolines using microwave assisted polymerization in 2004.[39] Until this 
time the synthesis of PAOx was slow, often taking > 6 hrs up to weeks, whereas similar results could 
be achieved using microwave heating in under 1 min. This enabled the relatively easy preparation of 
libraries of PAOx homopolymers and copolymers taking advantage of the variety in structures 
possible. As an aside, it is ironic that the recent discovery that low dispersity, high molar mass PAOx 
is feasible under meticulously dry conditions uses conventional lower temperature conditions and not 
microwave heating.[40]  
Technically, microwave heating made the synthesis of PAOx much more accessible, but its use as a 
biomaterial was strongly influenced by the discovery of its non-fouling properties by the group of 
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Textor.[41] By synthesizing poly(2-methyl-2-oxazoline) (PMeOx) grafted onto poly(L-lysine) they 
were able to attach the polymer as a mono-layer to negatively charged surfaces to show that PMeOx 
had slightly better anti-fouling properties compared to PEG. This was contrary to earlier findings by 
the group of Hubbell[42] who found that polyethylene terephthalate (PET) surfaces coated with high 
molar mass poly(2-ethyl-2-oxazoline) (PEtOx) had higher protein adsorption, and hence cell 
attachment, compared with polyethylene oxide (PEO). However, they compared only one molar mass 
of PEtOx with multiple molar masses of PEO and the exact composition and homogeneity of the 
PEtOx surface was not fully elucidated with some speculation that it changed over time. Especially 
interesting is the report by the group of Textor in which it was shown in a direct comparison that 
PAOx coated surfaces were more stable under oxidative conditions compared to PEG, ascribed to the 
side chain degradation mechanism of PAOx versus the main-chain degradation of PEG.[43] 
Two very recent developments that will potentially ensure the continued growth in interest in PAOx 
are the synthesis of high molar mass, low dispersity polymers using meticulously dry conditions[40] 
mentioned above, and the ‘first in human’ clinical trials[44] of a PAOx-drug conjugate. These two 
developments, reported by two different research teams, may be considered important developments 
needed for widespread use of PAOx in the biomedical field.  
This mini-review will provide an overview of very recent developments in hydrogels based on PAOx 
and aims to address the potential advantages of using PAOx hydrogels over other more established 
materials, including PEG, in the context of biomedical applications. It is not intended to be an 
exhaustive review of all work on PAOx hydrogels for which the reader is directed to excellent 
reviews by Adams and Schubert[18] in 2007, Kelly and Wiesbrock[45] in 2012,  and Hartlieb et al.[46] 
and Zahoranová and Kronek,[47] both in 2015. 
2. Biocompatibility and Excretion of PAOx 
Almost without exception, all the recent literature on PAOx hydrogels is targeted towards biomaterial 
applications, and while there are many in vitro studies with cell lines, or in some instances, primary 
cells, in vivo studies on implanted PAOx hydrogels are non-existent to the best of our knowledge. It is 
true that in vitro data is sufficient for PAOx-based sensor applications (discussed later),[48-50] but for 
any drug delivery, implant or tissue engineering application, in vivo data is critical to understand the 
degradation, circulation kinetics, excretion and immune responses. 
In the absence of these data we can speculate that PAOx hydrogels implanted into animals as 
drug/cell delivery devices or tissue engineering scaffolds will have some level of foreign body host 
response similar to other non-ionic synthetic hydrogels. For example, photo-crosslinked PEG is 
known to recruit macrophages when implanted subcutaneously in mice[51] as a result of non-specific 
protein adsorption, despite being widely considered as a low protein-fouling polymer. Given the 
similar physical properties of PAOx to PEG and shared low-fouling attributes,[41] a similar 
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inflammatory response may be anticipated if implanted in vivo. Of course, any chemical modification 
will influence the response, as will the animal species and site of implantation. What is important, 
though, is to design degradable hydrogels and to evaluate the fate of soluble degradation products 
(which can be predicted if degradable crosslinks are used) and non-crosslinked leachable polymer 
chains. Other oxidative degradation products may be expected as predicted by accelerated studies 
using reactive oxygen species.[52] Thus, in the near absence of literature on in vivo studies of PAOx 
hydrogels, it is worthwhile to discuss the animal studies on soluble PAOx as a proxy for how 
leachable and degradation products from hydrogels may be tolerated in vivo. 
A summary of all the in vivo studies on PAOx over the last 40 years are listed chronologically in 
Table 1. The first entry – the inclusion of PEtOx as an approved adhesive in food packaging, is an 
exception as it does not describe animal work but is relevant as it is the first formal acknowledgment 
that the polymer may be non-toxic. Of the studies from 1989 to 2017 it is interesting to note that half 
of them were reported in just the last three years, highlighting the maturation of PAOx technology for 
biomaterials. 
The studies listed in Table 1 can be crudely categorized into: 1) biodistribution of soluble polymers, 
2) biodistribution of liposomes or micelles (with and without loaded drugs), 3) toxicity and efficacy of 
polymer-drug conjugates, and 4) a hemostatic dressing. 
 
Table 1. Summary of in vivo studies on PAOx over the last 40 years. 
PAOx System Year Experiment Key Results Reference 
PEtOx 1977 - PEtOx listed as FDA 
approved adhesive in 
packaging for food 




1989 Biodistribution 125I 
labelled copolymers 
injected iv in mice 
Blood clearance measured 
after 24 hrs, accumulation in 
skin and muscle but not in 
organs of the mononuclear 
phagocyte system 
Goddard et al.[54] 
Lipids prepared from PMeOx or PEtOx 




iv into rats 
Long circulation times, 
protection from rapid 
recognition 
Woodle et al.[55] 
Lipids prepared from PMeOx or PEtOx 
(1.5-5 kDa) conjugated to 
distearoylphosphatidylethanolamine 
1996 125I loaded 
liposomes 
(polymer-lipid was 
5 mol % of  
phospholipid 
content) iv injection 
in mice 
Relatively long blood 
circulation times 
Zalipsky et al.[56] 
Radiolabelled PEtOx, PMeOx via end 
group chelator. 
2007 111In labelled 
biodistribution 
experiment in mice 
following iv 
injection 
Rapid clearance from the 
blood, predominately 
excreted via kidneys; slightly 
higher for PMeOx compared 
with PEtOx suggesting 
possible binding to plasma 








P(MeOx-b-ButOx-b-MeOx) copolymer 2010 Paclitaxel loaded 
micelles injected 
into Lewis Lung 
carcinoma tumour 
bearing mice  
Significant tumour burden 
after first injection of 
Paclitaxel loaded P(MeOx-b-




PMeOx, PEtOx, PPropylOx 2011 Insulin conjugates 
iv to rats; BSA 
conjugates into 
rabbits and tested 
for antibodies; 
toxicity based on 
acute and chronic 
dosing in rats  
Sustained lowering of blood 
glucose in rats; attenuation of 
BSA immunogenicity; high 
maximum tolerated doses in 
rats 
Viegas et al.[59] 
PEtOx-polylactic acid-
polyethyleneimine micelles 
2014 Delivery of mini-
circle DNA and 
doxorubicin to a 
breast cancer mouse 
model 
Good gene expression and 
retention of the micelles 
within the tumour cite with 
little gene expression in the 
spleen, kidneys, liver and 
lung. 
Gaspar et al. [60] 
PMeOx conjugated liposomes 2015 Injected into rats 
and mice and 
circulation times 
measured. 
Rapid clearance after second 
injection due to possible IgM 
response 
Kierstead et al.[61] 
89Zr labelled PEtOx-desferrioxamine 
chelator  
2016 Micro Positron 
Emission 
Tomography of 
mice injected iv and 
ex vivo 
biodistribution 
Rapid clearance for 20, 40 
kDa, higher molecular weight 
leads to longer blood 
circulation times, some tissue 
accumulation above 70 kDa  
Wyffels et al. [62] 
89Zr and 18F labelled PEtOx 2017 Micro Positron 
Emission 
Tomography of 
mice injected iv 
Rapid clearance of 5 kDa 
polymers 
Glassner et al.[63] 
PEtOx-rotigotine conjugates 2017 Multiple small 
animal studies, 
monkeys, humans 
Sustained levels of free 
rotigotin in plasma of 
monkeys following cleavage 
from PEtOx backbone; 
improved ‘on time’ in MPTP 
model monkeys; improved 
rotational behavior in 6-
OHDA lesioned rats; high 
clearance rates via kidneys; 
safety demonstrated in first-
in-man phase I clinical trial 
Moreadith et al.[44]  
PAOx-NHS coated on a collagen 
sponge 
2017 Heparinised pigs Hemostasis achieved  Boerman et al.[64] 
125I labelled PEtOx-doxorubicin 
conjugates 




Gradual blood clearance with 
some accumulation in the 
tumor, spleen and liver. 
Reduction in volume of 
tumor.  
Sedlacek et al.[65] 
 
 
The hemostatic dressing listed in the Table above is the only animal study of a material resembling a 
PAOx hydrogel to date. In their study, the group of Van Hest[64] together with tissue-sealant company 
GATT Technologies, used N-hydroxysuccinimide (NHS) ester functional copolymer of 2-n-propyl-2-
oxazoline (PropOx) and 2-methoxycarbonylethyl-2-oxazoline (MestOx[66]) coated onto a collagen 
sponge. Even though this is not a PAOx hydrogel, the excess NHS ester groups crosslinked with 
blood and ECM proteins to in situ form a hydrogel coating that induces blood clotting and stops 
bleeding (Figure 2). A test of the most promising composition with the shortest gelation time (<1 min) 
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was used to test the suitability of the dressing as a hemostatic agent towards bleeding in heparinized 
pigs. Other than an assessment of the bleeding no adverse effects of the polymer were reported. 
 
Figure 2: Left: Schematic showing preparation of a PAOx-NHS coating on a gelatin sponge as a 
hemostatic dressing; Right: the dressing on a pig spleen at 0 and 5 minutes. Adapted from Boerman et 
al.[64] 
 
Of the studies examining liposomes, long circulation times are reported in all cases with the exception 
of Szoka and co-workers[61] who observed accelerated blood clearance after a second injection of 
PMeOx conjugated liposomes into Male Wistar rats. Even though the half-life of 30.5 ± 1.3 hours 
after the first dose was one of the highest for the polymers studied, the half-life dropped to only 1.9 ± 
0.5 hours after the second dose. They postulate that this is due to the generation of anti-PMeOx-IgM, 
similar to the anti-PEG-IgM found in 25% of healthy blood donors. More general, they found a 
correlation between high polymer intrinsic viscosity and good circulating times after the first 
administration and accelerated clearance after the second administration. The explanation for this 
observation is still under investigation and it is unclear whether the use of rather ill-defined PMeOx 
(dispersity around 1.4) is related to the observed effect. 
 
Unlike liposomes, soluble PAOx is rapidly cleared from the blood and shows little tissue 
accumulation below approximately 70 kDa.[62] The first study of biodistribution by Goddard et al. 
reported in 1989 using 125I labelled PMeOx-co-2(4-hydroxyphenyl)-2-oxazoline found some 
accumulation of the tracer in the skin and muscle.[54] A similar study on PMeOx and PEtOx by 
Gaertner, Luxenhofer et al.[57] found negligible tissue accumulation and postulate that the earlier 
Goddard et al. study lacked the control over polydispersity meaning the tissue accumulation could 
have been due to high molecular weight fraction. 
 
In summary it appears there is overwhelming evidence that soluble PAOx is well-tolerated and does 
not accumulate in the body. Therefore, it should be possible to design implantable or injectable PAOx 
hydrogel devices of which the leachable or degradable products are expected to cause no harm. What 
is less known is how the body will react to the hydrogel itself? If PEG hydrogels are a guide, then 
8 
 
caution needs to be employed. For instance, one of the largest studies involving implanted PEG 
hydrogels was in the 1990s investigating PEG hydrogel coatings on pancreatic islets with the aim of 
reducing the need for immunosuppression for type I diabetes recipients. While promising results were 
observed in rodents, the study failed in non-human primates due to aggressive reaction to the 
coatings.[67] This highlights the dangers in extrapolating from small animals to large animals, or 
indeed, from in vitro to any animal study, yet at the same time can help guide experimental design 
used with PAOx hydrogels in biomedical applications. 
 
3. Recent Developments in PAOx Hydrogel Synthesis 
One of the most prolific periods of research on innovative crosslinking chemistry for PAOx was in the 
late 1980s and early 1990s single-handedly by the group of Chujo and Saegusa who published at least 
a dozen articles[21-32] revealing new ways of forming crosslinked networks based on PAOx. Their 
work has been reviewed before (e.g. in the review articles mentioned earlier) and so will not be 
discussed here other than to mention that their work was almost exclusively focussed on the synthesis 
of the polymers and crosslinking chemistry and the stability of the gels without investigation of 
potential applications (at least in the open literature). Since the work by Chujo and Saegusa, the 
number of new functional PAOx has increased significantly[68] and, hence, the variety in crosslinking 
chemistry has expanded too. The discussion here will be confined to very recent developments; note 
that some of the references used here will appear again in the later section on applications where 
appropriate. 
3.1 Crosslinking During Polymerization 
The formation of a continuous network during polymerization of 2-alkyl-2-oxazoline monomers via 
the inclusion of a bis-2-oxazoline is a scale-able, convenient and rapid method for creating hydrogels 
not readily accessible with other non-ionic hydrogels (e.g. PEG, PVA). The disadvantages, however, 
are that the networks are non-degradable, and because the reaction mixture must be heated to high 
temperatures and performed in absence of water, the swelling in water and any incorporation of 
biologics can only occur after network formation and solvent removal. 
In a demonstration of the versatility of the polymerization-gelation method, Kronek and co-workers 
synthesized a series of hydrogels from EtOx and a homologous series of three bis(2-oxazoline) 
crosslinkers, with butyl, hexyl or octyl spacers between the 2-oxazoline rings and methyl-4-
nitrobenzenesulfonate as an initiator with a polymerization temperature of 110 °C for 5 hrs.[69] As 
expected, an inverse relationship between the swelling of the hydrogels in water and the length of the 
alkyl spacers in the bis(2-oxazoline) crosslinkers was observed. The moduli of the hydrogels 
increased with increasing crosslinker content and spacer length, attributed to a higher proportion of 
inter-chain crosslinking for longer spacers. Toxicity experiments of extracts with 3T3 fibroblasts 
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revealed some toxicity attributed to residual monomer and benzonitrile (their polymerization solvent) 
while growing cells on the hydrogels was most successful for the soft hydrogels. It should be noted 
that a number of factors, including leached compounds, substrate stiffness and protein adsorption 
from the media, will all play a role. Some insight into the intended application of the hydrogels was 
evident from their experiments involving freeze drying of the hydrogels to introduce porosity, similar 
to Hickey and co-workers,[70] followed by seeding of pancreatic β cells inside the pores which formed 
aggregates and remained viable for 12 days. 
Schubert and co-workers also used a bis-functional 2-oxazoline to form networks with EtOx, but with 
a phenyl group as the spacer.[71] Their  new phenyl-1,4-bis-oxazoline  is a structural isomer of the 
previously reported crosslinker phenyl-1,3-bis-oxazoline reported by Wiesbrock and co-workers[72] 
and was used for the first time to form a gel during CROP of EtOx in a one-pot, microwave assisted 
reaction. The highest gel fraction reported was 84% and solid and swollen state NMR spectroscopy 
identified a small amount of crosslinking incorporated through just one of the bis-oxazoline rings. The 
hydrogels were investigated for stabilization of coagulation factor VIII as a more convenient storage 
method rather than preparing from dry powder immediately before injections. Their hypothesis is that 
the pseudo-peptidic structure of PAOx may lead to a high affinity, and hence improved stabilization, 
between the polymer and protein. Their test method consisted of loading multiple hydrogels into well 
plates, washing and addition of factor VIII, incubation and then centrifugation and measurement of 
residual factor VIII activity. It was observed that the crosslinking density was highly influential 
towards protein stability yet stability at 7 days was significantly improved compared with any of the 
controls.  
 
3.2 Crosslinking of Polymeric Precursors 
The use of polymeric precursors to create PAOx hydrogels is more complex than the methods 
described above, but it is an attractive alternative as it allows for potentially better control over the 
network structure and may be used to reduce toxicity during the crosslinking process due to the low 
energy input required to go from soluble functional polymers to an insoluble network. Furthermore, 
the issues associated with residual monomers or solvent leaching post-gelation can be avoided. That is 
not to say that all polymeric precursor approaches use non-toxic crosslinking conditions and there are 
many examples of inclusion of organic solvents,[29, 73] toxic reagents,[22, 25] heat,[23] and high energy 
radiation[74] being used in crosslinking. If, however, water soluble macromonomers are used with mild 
crosslinking reactions, then it is possible to form gels under non-toxic conditions. Most of the studies 
to date include only proof-of-principle cell toxicity studies and no long-term or in vivo data exists yet 
other than that of Van Hest and co-workers[64] discussed in Section 2. 
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Many of the functional 2-oxazoline monomers are hydrophobic, however, copolymerizing with 
hydrophilic monomers can lead to water-soluble polymeric precursors. For example, 
copolymerization of 2-undecenyl-2-oxazoline (DecenOx) with EtOx results in statistical copolymers 
soluble in ethanol[73] that form micelles in aqueous conditions.[75] Conversely, when DecenOx is 
copolymerized with the more hydrophilic MeOx, the product with DecenOx content up to 5% is water 
soluble.[7, 76, 77] The ability to retain water solubility even when using hydrophobic monomers such as 
DecenOx is a function of the high hydrophilicity of PMeOx. The striking degree of hydrophilicity of 
PMeOx has been demonstrated using HPLC to show even greater affinity for water compared with a 
column stationary phase than PEG.[59] Nonetheless, in our recent work[76] we found that there is a 
certain degree of hydrophobic association between the hydrophobic DecenOx groups resulting in 
highly efficient photo-gelation consisting of competition between the thiol-ene radical addition 
reaction and vinyl homocoupling. The same phenomenon was not observed with PMeOx-ButenOx 
copolymers.  
The use of aqueous conditions for crosslinking is not a prerequisite if biologics are not being used and 
organic solvents can be utilized to increase the range of crosslinkers used. Kronek’s group[78] used 
dithiothreitol, 1,3-propanedithiol, 1,6-hexanedithiol and 1,9-nonanedithiol to crosslink copolymers of 
PMeOx-ButenOx or PEtOx-ButenOx (each in a comonomer ratio of 90:10) in 20% ethanolic 
solutions using 365 nm light irradiation. Following gelation, the ethanol was exchanged to water and 
toxicity determined on extracts and in direct contact with 3T3 fibroblasts. The extracts were found to 
be toxic in high concentrations but in all cases direct contact toxicity was low, and similarly to the 
previous work by the same group,[69] the more hydrophobic the crosslinker the lower the swelling. he 
softness of the hydrogels was also measured using a small-probe indentation method revealing 
relatively low moduli in between 6.3 kPa and 128 kPa for the most and least swollen hydrogels, 
respectively.  
The group of Luxenhofer has also used MeOx as a monomer to prepare water-soluble PAOx to 
encapsulate cells for biofabrication[79] (discussed more in section 4.2.3). Rather than using a 
chemically crosslinking system, they found that CROP of 2-n-propyl-2-oxazine using methyl triflate 
(MeOTf) as the initiator followed by addition of a PMeOx block to the living system resulted in 
polymers that would thermally gel around 20-40 °C, depending on composition. The use of 2-
oxazines in combination with 2-oxazolines is a novel way of extending the range of possibilities of 
this class of polymers also recently highlighted by Kempe.[80] 
The use of telechelic PAOx as the crosslinker is another method for making networks and takes 
advantage of the facile and, arguably under-utilized, end-group functionalization available during the 
termination step of the CROP of 2-oxazolines. The group of Tiller recently expanded on their work 
into PAOx based conetworks comprising of nanostructured interconnected polymer phases by 
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polymerizing di-methacrylamide terminated PMeOx with butyl acrylate in 1-methoxy-2-propanol as 
the solvent. The macromolecular crosslinker was prepared by using a difunctional initiator, p-
dibromoxylene, followed by termination of the polymerization with DMAP-methylacrylamide to 
achieve 95% functionalization.[81] These conetworks were used to activate lipase from C. antarctica 
for application in organic solvent enzymatic catalysis. 
The telechelic PAOx approach has also been used by the group of Jordan who synthesized di-
methacrylate terminated PMeOx (using methacrylic acid to terminate) and mixed methacrylate-alkyne 
PMeOx (using propargyl p-toluenesulfonate as the initiator and methacrylic acid to terminate the 
reaction).[82]  The α-alkyne-ω-methacrylate was subsequently used in a Huisgen cycloaddition ‘click’ 
reaction to incorporate a disulphide core to the crosslinker. The microbeads synthesized from these 
telechelic PMeOx crosslinkers are described more in Section 4.2.1.  
3.3 Irradiation 
Ionizing radiation is an attractive method for modifying polymers and has a long history in polymer 
processing, especially in creating a variety of crosslinked materials from hydrogels[83] to 
fluoropolymers.[84] Radiation processing of PAOx, however, has received very little attention in the 
literature. The group of Voit created nanogels using 20 kGy dose of electron beam irradiation of 
poly(N-isopropylacrylamide) (PNiPAAm) grafted with poly(2-carboxyethyl-2-oxazoline)[85] or 
PEtOx,[86] whereby crosslinking was assumed to occur through the dense hydrophobic PNiPAAm core 
with no mention of the radiation chemistry of the PAOx component. 
Around the same time as the reports by Voit, Ali and AlArifi reported hydrogels prepared from 
mixtures of PEtOx and acrylic acid (no solvent was mentioned so we must assume the acrylic acid 
was the solvent for PEtOx) that were irradiated up to 40 kGy. However, when the PEtOx content was 
increased no gel was observed leading them to conclude that PEtOx is not a radiation cross-linkable 
polymer.[87] Very recently Sedlacek et al.[88] found the opposite. They examined the potential for 
electron beam and gamma irradiation to be used in sterilization of PAOx and found that for dilute 
solutions (1-5 wt. %) of PEtOx in water, hydrogels were formed in yields of 60-85% with >5 kGy for 
electron beam and >50 kGy for gamma irradiation. A mechanism for crosslinking is proposed via a 
radical formed at the methylene on the ethyl side chain as a result of C-H dissociation, presumably to 
form H-type crosslinks following combination with the same species of radical on an adjacent chain. 
The authors mention on-going work exploring this somewhat serendipitous result.  
It appears that the radiation conditions are highly determinant as to whether a network is obtained or 
not. The solvent, concentration, polymer molar mass and radiation dose are all important. Sedlacek et 
al.[88] also report the irradiation of solid PEtOx and show chain scission. This is consistent with our 
work on irradiating solid PEtOx and PEtOx plasticized with a small percentage of water which 
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showed predominantly chain scission by size exclusion chromatography when exposed to gamma 
radiation up to 100 kGy (unpublished data).  
In summary, the variety and sophistication of the crosslinking methods for PAOx continues to grow 
taking advantage of the possibilities of incorporating functionality in the initiating group residues, 
terminating agents, backbone and side-chains. Other methods, such as irradiation, offer a relatively 
cheap and highly scalable method for producing PAOx hydrogels. 
 
4. Emerging Applications 
4.1 Drug Delivery 
PAOx has been used as a drug delivery carrier in the form of nanoparticles,[58, 89] soluble polymer-
drug conjugates[44, 59] and eroding systems,[90, 91] but very few studies have been reported using PAOx 
hydrogels or other networks for drug delivery. Considering the possibilities of making PAOx gels 
with custom polarity and swelling, these could be viewed as attractive drug delivery systems 
compatible with a range of drugs and tailored release profiles. 
The group of Wiesbrock[92] have demonstrated this approach by making libraries of hydrogels 
incorporating ethyl, butenyl, nonyl, and decenyl side-chains that were used to encapsulate active 
pharmaceutical ingredients (APIs). They used two routes to synthesize the hydrogels – either using 
bifunctional monomers prepared via thiol-ene photochemistry of alkene functional 2-oxazoline 
monomers with dithiols including an ester as degradable linker followed by microwave assisted 
polymerization, or first the formation of polymers followed by thiol-ene photo-crosslinking. The post-
polymerization crosslinking method allowed for incorporation of ibuprofen or eosin B. The latter was 
used for a release study with a terpolymer of PEtOx-NonOx-ButenOx revealing that at higher pH 
more eosin was released. Interestingly, there was no burst release and the increase in eosin in solution 
over time was linked to the hydrogel degradation via hydrolysis of the ester containing crosslinker; 
this may suggest that the eosin was physically bound to the polymer which supports our findings that 
the use of eosin will stain PAOx hydrogels.[70] The work by the group of Wiesbrock follows on their 
previous study imbibing and releasing small molecules to and from hydrogels prepared with a wide 
range of 2-oxazoline monomers varying in hydrophilicity.[72] 
Not only are PAOx hydrogels attractive for delivery of small molecules, but they have also been used 
with silver ions for antimicrobial coatings. The group of Demirel[93] used different molar mass PEtOx 
hydrogen bonded with tannic acid in a layer-by-layer approach to encapsulate silver nanoparticles. 
Films up to 80 nm thick were achieved using the dip coating method, which degraded at high pH, 
releasing the silver. Although the films are proposed as antimicrobial coatings, no bacterial assays 
were presented in that study.  
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Drug delivery using nanogels for cellular uptake is a method for delivery payloads directly to cells. 
Schubert and co-workers synthesized block copolymers of EtOx and Boc-protected 4-amino-butyl-2-
oxazoline, followed by cleavage of the Boc group to create the free amine (Figure 3).[94] Subsequent 
preparation of self-assembled nanoparticles was performed by glutaraldehyde crosslinking via the free 
amine groups and titration of residual aldehyde groups with 6-aminofluorescein. By varying the 
amount of glutaraldehyde, the zeta potential of the nanogels could be modified based on the amount 
of free amine groups as a way of modulating cellular uptake. As their ultimate application is cell 
targeting following injection into the bloodstream, long circulation times are desirable, similar to the 
PAOx lipid studies summarized earlier in Table 1. Although this group did not perform circulation 
studies they did investigate their nanogels for induced hemolysis and erythrocyte aggregation and 
found no significant interaction of the nanogels with blood. Other recent studies on PEtOx modified 
nanoparticles[95] and PMeOx coated viruses,[96] each without the ability to vary the zeta potential, 
similarly found reduced interaction of PAOx modified materials with cells. 
 
Figure 3: Structures of PEtOx-b-4-amino-butyl-2-oxazoline before and after deprotection of the Boc 
groups and schematic of the micellular encapsulation of 6-aminofluorescein. Taken from Hartlieb et 
al. [94] 
4.2 Cellular Constructs 
4.2.1 Cell Therapies 
Cell therapies have long been hyped as a panacea for numerous disease states, with stem cells 
receiving the highest of expectations. Some of the promise of cell therapies has recently been realised, 
not from stem cells but from gene-modification of T cells. Very recently a new gene-modified 
immunotherapy, chimeric antigen receptor T-cell therapy (CAR-T), was approved by the Food and 
Drug Administration to treat leukemia and is expected to be followed by many other similar products. 
The role that hydrogels play in cell therapies will be minor, but nonetheless important. For instance, 
hydrogels can aid in the expansion of cells or carriers for transplantation. 
The good tolerability of soluble PAOx in the body (Table 1) and the ability to create degradable 
hydrogels make PAOx hydrogels an interesting and emerging candidate material for use in cell 
therapies. A recent study by Jordan’s group[97] used the surface of PAOx beads for neuronal cell 
culture ultimately intended for transplantation. Their beads were synthesized using an emulsion 
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polymerization of HEMA or 2-methacryloxyethyltrimethylammonium (METAC) with a PMeOx30 
dimethacrylate crosslinker prepared from the difunctional initiator, trans-1,4-dibromo-but-2-ene 
(Figure 4). The size of the beads from the emulsion process was quite disperse but could be 
selectively sieved to a range of 30-250 μm. The PAOx itself was passive whereas the positive charge 
of METAC ensured cell adhesion. Neither rat primary hippocampal neuronal cells nor the more 
adhesive HEK cells adhered to HEMA-PMeOx spheres and attempts to coat with poly(L-lysine) 
(PLL) via LbL proved problematic, but replacement of the HEMA with METAC improved HEK 
adhesion but not neuronal cells unless the PLL was also included. 
  
Figure 4: Precursors and structure of PMeOx-HEMA networks based on PMeOx-dimethacrylate 
synthesized from the difunctional initiator, trans-1,4-dibromo-but-2-ene and laser scanning confocal 
microscopy images of fluorescently stained HEK and neuronal cells on microgel particles. Modified 
from Platen et al.[97] 
The same group later reported a continuous microfluidic method to produce uniform microbeads with 
a tailorable diameter of 50 to 500 µm without the need for sieving as an improvement over the 
emulsion batch process.[82] They used a short telechelic dimethacrylate PMeOx30 crosslinker and a 
degradable disulphide PMeOx crosslinker (discussed earlier) to crosslink HEMA, METC or SPMA 
monomers. By varying the ratio of monomer to PMeOx crosslinker the elasticity of the beads was 
varied from ca. 2 to 20 kPa to mimic different tissue types. When bone marrow derived human 
mesenchymal stem cells (hMSCs) were grown on the bead surfaces it was found that without any 
charged groups (i.e. PMeOx-HEMA) no cell adhesion was observed but with positive (PMETAC) or 
negative (METAC) charges high numbers of cells attached. Attempts to coat PMeOx30-HEMA beads 
with collagen to improve cell adhesion were unsuccessful due to lack of protein adherence but it did 
work for the charged systems. To address the issue of toxicity of degradation products (if they were to 
be transplanted into an animal) the workers used glutathione to cleave the disulfide group of the 
crosslinker and then studied the molar masses. Structurally, they highlight that the degradation 
products will contain water soluble PMeOx of low molar mass that should be excreted. SEC 
measurements confirmed this. Although no animal studies of implanted PAOx materials exist, the in 
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vivo data on soluble materials (Table 1) can still be used to infer if the materials will be well-tolerated 
in the body.  
 
4.2.2. 3-Dimensional In Vitro Models 
Three-dimensional (3D) hydrogel in vitro tissue models are physiologically more relevant than 
traditional 2-dimensional flat surface cell culture and can provide pre-animal model data, or 
eventually replace animal experiments completely. A number of natural and synthetic polymer 3D 
hydrogels exist each with their own advantages and disadvantages.[98-100] One advantage of using 
PAOx for in vitro models is the possibility of adding biological signalling molecules to the side-
groups to promote cell function.[101] One of the first demonstrations that cell adhesion to PAOx 
hydrogels can be controlled used the ubiquitous RGD integrin binding minimum peptide sequence. 
The peptide was incorporated into the side-chains by thiol-ene photo-conjugation and photocuring to 
DecenOx copolymers using cysteine terminated RGD (viz. CRGDSG) and dithiothreitol, 
respectively.[7] In the same study, proof-of-principle experiments showed that it was possible to 
encapsulate fibroblasts within photocured hydrogels, although multiple time-points were not 
collected. Similarly, a study examining the MCF-10A epithelial cell line seeded onto PAOx hydrogels 
with and without RGD peptide showed little cell adhesion without the peptide but good epithelial 
colony formation on the hydrogels with peptide.[101] An extension of this work with a breast cancer 
cell line, MDA-MB-231, on non-degradable and MMP-degradable hydrogels showed the spheroid 
morphology similar to that found in breast cancer could be achieved with the MMP-degradable 
sequence used to crosslink the hydrogels (Figure 5; unpublished data).  
An alternative method for encapsulating cells within PAOx hydrogels was demonstrated by Hickey 
and co-workers in their work to create artificial female reproductive tract tissue ultimately aimed as a 
template for studying infection.[70]  PMeOx-DecenOx hydrogels were frozen and lyophilized to 
introduce pores with areas of 200 μm2 to 3200 μm2. This porosity range made it possible to seed cells 
(HFF1 human fibroblast cells and primary fallopian tube stroma cells) on top of the hydrogels and 
have them infiltrate into the bulk of the hydrogel, hence avoiding any potential DNA dimerization 





Figure 5. MDA-MB-231 cancer cells grown on top of PMeOx-DecenOx hydrogels without (left) and 
with (right) an MMP substrate crosslinker. Without the MMP degradable crosslinker the cells spread 
evenly on the surface but with the MMP degradable crosslinker the cells form spheroids and migrate 
into the hydrogel as indicated by the z-axis profile on the top and left of each image (unpublished 
data). 
 
4.2.3 Biofabrication  
A new field related to cell therapy and 3D cell culture is biofabrication (also called additive 
biomanufacturing). Instead of only delivering cells or manually making cell-hydrogel constructs, 
biofabrication aims to create tissue-like structures aided by a digital input signal. Similar to ‘Tissue 
Engineering’ (defined as ‘the development of biological substitute to restore, maintain, or improve 
functions.’[102]), biofabrication involves the generation of biologically functional products using 
automated bioprinting or bioassembly techniques followed by maturation of the functional 
product.[103] A technical challenge for biofabrication is the development of ‘bioinks’ – carrier 
materials able to be printed in the presence of cells. For this, hydrogels are an obvious choice but the 
concept of printing hydrogels is not new. For instance, Calvert and Liu reported freeform fabrication 
of polyacrylamide/acrylic acid/methacrylic acid with silica as a thixotrope 20 years ago.[104] The 
challenge today is to create printable materials that are also non-toxic, can be loaded with cells, and 
processed without harming cells (e.g. excess shear stresses).  
The group of Luxenhofer have recently reported a ‘biocompatible ink’ from a triblock copolymer with 
a poly(2-n-propyl-2-oxazoline) middle block and PMeOx outer blocks, described earlier in Section 
3.2.[79] This polymer has temperature gelling properties, which was serendipitously discovered when 
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freezing a sample for lyophilization. Furthermore, the hydrogel has sheer thinning properties making 
it suitable for extrusion based printing. Small angle neutron scattering (SANS) analysis of the gel 
suggested an unusual bicontinuous sponge-like structure. What is particularly intriguing about this 
system is the ability to retrieve the encapsulated cells by lowering the temperature which could be 
useful if the cells are to be characterization by methods such as flow cytometry. In a proof-of-
principle experiment they created a 0◦/90◦ laydown pattern of a single layer of hydrogel/cell composite 
with good cell distribution and >90% cell viability of NIH-3T3 cells. 
Another technique related to biofabrication is melt electrowriting (MEW). Traditionally used with 
thermoplastic polyesters[105] and polyolefins,[106] MEW has recently been used to make 3D fibrous 
structures from PEtOx.[107] By heating the polymer to 200-220 °C, well above the Tg, and applying 3-7 
kV to charge the polymer, Groll and co-workers were able to achieve sufficient flow of the molten 
PEtOx to result in electrospun fibres of diameter 8-138 μm. By using a digitally-controlled translating 
collector they were able to precisely position the fibres to make 3D structures. The study was the first 
to use MEW with PEtOx and, although not mentioned, the resulting fibres would be presumably 
dissolve in water given the good water solubility of PEtOx, so some modification would be required 
to make hydrogels. 
One way to make fibrous hydrogels of PAOx was reported by the group of Sanyal.[108] Unlike the 
MEW work described above, here solution electrospinning was used to create nanofibrous mats of 
PEtOx-ButenOx mixed with multifunctional thiol crosslinkers and a photoinitiator. Exposure of the 
electrospun fibers to UV irradiation during spinning resulted in a hydrogel retaining the fibrous 
features of the electrospun mat when swollen in water. The same approach could conceivably be used 
with the MEW process or other fused deposition modelling processes, however, these techniques can 
be demanding on the amount of material needed during printing optimization or filling of dead 
volumes in the machines. This bottleneck may clear once commercial quantities of functional PAOx 
become available.  
An alternative to MEW or electrospinning to create structured PAOx hydrogels is the use of sacrificial 
templating. Our group showed that precisely controlled micro-sized channels can be incorporated into 
PEtOx-ButenOx hydrogels by using a 3D printed sacrificial poly(ε-caprolactone) fibrous structure 
created using MEW.[77]  This approach could be used to make hydrogel-based microfluidic devices or 
tissue engineered constructs with vascular-like features. 
4.3 Coatings and Sensors 
Earlier in this article it was described how pioneering studies by the group of Textor revealed that 
under certain conditions, PMeOx functionalized surfaces can exhibit lower protein adsorption when 
compared to PEG surfaces prepared in the same way.[41] This work has motivated others to examine 
PAOx coatings for biomaterial and biosensor applications and although they may not necessarily be 
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defined as classical hydrogels, many of the coatings have hydrogel-like properties in that they are 
insoluble but highly swollen and may contain some crosslinking, hence their inclusion in this 
discussion.  
What is most striking about the research into PAOx coatings is the variety in findings when 
examining cell attachment. Some of this can be attributed to the different cell types being used and 
cell lines versus primary cells, and some of it to the type of PAOx and the preparation method. For 
instance Davies and co-workers[109] exploited the living nature of PAOx synthesis to conjugate 
PMeOx, PEtOx, poly(2-isopropyl-2-oxazoline) (PiPropOx) or poly(2-butyl-2-oxazoline) (PButylOx) 
to amine-functional glass slides by using amino-functionalized glass slides as the terminating group 
for the CROP. Regardless of the type of polymer used, both epithelial and fibroblasts cell lines were 
able to grow to confluency. Similarly, Dworak and co-workers showed confluent dermal fibroblasts 
on PiPropOx and poly(EtOx-2-nonyl-2-oxazoline) on glass at 37 oC. Interestingly, they were able to 
remove the cell sheets without enzymatic or mechanical stimulation by dropping the temperature to 
20 °C – below the cloud point temperature of the polymers – leading to hydration and swelling of the 
coating.[110, 111] 
The group of Wang have also studied antifouling with the aim of making coatings more stable than 
PEG in vivo.[112, 113] One of their systems was based on block copolymers of PMeOx-poly(4-vinyl 
pyridine) adsorbed onto silicon wafers and polymethylmethacrylate sheets that were stabilized by 
crosslinking via hydrogen-bonding of the poly(4-vinyl pyridine) blocks with polyacrylic acid.[112] The 
block copolymer was synthesized by taking advantage of the direct incorporation of an alkyne group 
via the use of propargyl-p-toluenesulfonate as the initiator for CROP of MeOx followed by coupling 
the resulting polymer using Huisgen cycloaddition to azide-terminated poly(4-vinyl pyridine) 
synthesized by atom transfer radical polymerization (ATRP). In their other system, hydroxyl-
terminated PMeOx was reacted with hexamethylene diisocyanate to create PMeOx with a terminal 
isocyanate group to be subsequently coupled to hyperbranched polyethylene imine (PEI).[113] The 
resulting PEI-g-PMeOx was deposited onto solid substrates by mixing with dopamine under alkaline 
conditions to create a polydopamine-PEI-g-PMeOx coating. In both studies with PMeOx-poly(4-vinyl 
pyridine) or PEI-g-PMeOx, the coated substrates were found to have low bovine serum albumin 
(BSA), platelet and HUVEC adhesion up to 28 days in vitro. Similar results were recently reported by 
the same group for brush copolymers of PMeOx-poly(4-vinyl pyridine) synthesized by reversible 
addition-fragmentation chain transfer (RAFT) polymerization of a PMeOx-methacrylate 
macromonomer synthesized by capping the CROP of MeOx with methacrylic acid.[114] 
An alternative to coating linear polymers to surfaces is to use cyclic polymers. Cyclic PAOx can be 
prepared based on linear telechelic PAOx synthesized with propargyl p-toluenesulfonate as the 
initiator and 2-azidoethylamine as the terminator followed by intramolecular Huisgen cycloaddition in 
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dilute solution.[115, 116] When immobilized onto surfaces, the cyclic brushes produced surfaces with 
higher polymer density and superior protein resistance compared with linear analogues. This example 
is a clear demonstration of applying elegant polymer synthesis to create intriguing new surfaces. 
Partially hydrolyzed PAOx was a theme exploited by Chujo et al. in a number of their studies[21, 24, 25, 
28, 29] to introduce secondary amines into the PAOx backbone for further modification and is an 
approach used recently by the group of Konishi to make PAOx gels for sensor applications.[117] They 
partially hydrolysed a copolymer of PMeOx and PEtOx and subsequently used the resulting 
ethyleneimine units to conjugate a pyrene derivative and to crosslink using hexamethylene 
diisocyanate. The resulting gels were amphiphilic and exhibited shifts in fluorescence with changes in 
swelling, i.e. solvatochromic properties. 
The diversity of emerging applications utilizing PAOx highlights the utility and versatile nature of 
this class of polymers. What is also noteworthy is the number of different groups now working on 
gels and coatings using PAOx and it will be interesting to see which of these applications will 
progress to translation. Having considered the work reported to date, in the next section we speculate 
where the field of PAOx hydrogels will be moving in the coming decade. 
5. Future Directions 
There has been tremendous interest in using PAOx for self-assembling nanoparticles, drug reservoirs 
and conjugates in the last decade. Yet, their use in hydrogels is still under-represented. This is despite 
the advantages of PAOx compared with PEG of: 1) a variety of side chains to modulate 
hydrophilicity, 2) possibilities to include reactive side-chains, 3) ability to incorporate functional 
groups to the α and ω termini via judicious choice of initiators and terminating conditions, 4) 
thermoresponsive properties, and 5) potentially more favourable immuno-response compared with 
PEG (relevant for in vivo applications). Given these attractive features of PAOx for hydrogel 
synthesis it is worth exploring how the field may evolve in the coming years. 
5.1 Polymer Architecture 
One area that may see growth is new PAOx hydrogel architectures. Because covalent crosslinking of 
PAOx through side-chains can result in significant undesired intramolecular reactions it would be of 
interest to explore other polymer architectures. A recent modelling study of generalized model ‘click’ 
networks highlighted the interplay between structure and the subsequent ratio of loops to branches 
after crosslinking.[118] Although block and random copolymers of PAOx are readily achievable, 
star[119, 120] or hyperbranched systems are less common and almost unused for preparing hydrogels. An 
exception is a report on crosslinking of star PAOx in 1992 by Chujo et al. representing one rare 
example of using star-shaped PAOx gel precursors.[121] In that work the tri-functional initiators, 1,3,5-
tris(iodomethyl)benzene or 1,3,5-tris(p-toluenesulfonyloxymethyl)benzene were used in the CROP of 
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MeOx and terminated with benzylamine. The star polymers were subsequently crosslinked as ca. 10% 
solutions in DMF with hexamethylene diisocyanate and a catalyst. It is important to note that the 
reactivity of the tri-functional initiators decreased as each electrophile was consumed such that each 
arm would have been of different length. Furthermore, the terminal benzylamino functionalion degree 
of each star was poor. This was manifested in the gels which had a maximum yield of 44% and 
swelling up to nine times in water.  
Hyperstars may be an alternative to star polymer gel precursors. Lambermont-Thijs et al.[122] capped 
living chains of PEtOx with amine-functional dendrimers and more recently the group of Perrier[123] 
reported PAOx hyperstars starting from a tri-allyl core and a thiol-yne monomer. The photo-coupled 
core was extended with a thiol terminated PEtOx by one pot termination of PEtOx polymerisation 
with potassium ethyl xanthate followed by aminolysis with dimethylamine to form a thiourea and the 
mono-thiol-functionalized PEtOx. Their application was drug delivery vectors but it is conceivable 
that the hyperstars, with some modifications, may have further use in hydrogel synthesis.  
5.2 Crosslinking Chemistry 
Other than polymer architecture, the crosslinking chemistry is a source of constant innovation. Recent 
developments in crosslinking chemistry has been discussed earlier in this article, but there remain 
opportunities to exploit much of the same chemistry as used in self-assembling nanoparticles, as drug 
reservoirs and conjugates, which could also be used for creating hydrogels. For example, Groll and 
co-workers[124] recently reported the modification of PMeOx-Butenox/DecenOx copolymers with 
mercaptothiazolidine using thiol-ene photo-chemistry followed by deprotection to reveal a cysteine 
group capable to further modification using native chemical ligation with a thioester-containing 
pentamer or 20-mer. Clearly the same chemistry could be used to create hydrogels with only slight 
modifications. Likewise, strain-promoted azide–alkyne cycloaddition (SPAAC) is an example of a 
conjugation tool that has been adapted to create PEG hydrogels[125] and could equally be applied to 
PAOx with only minor modifications to the previously reported bicyclo[6.1.0]non-4-yne terminated 
PEtOx.[63] Similarly, glyco-PAOx,[126] POxylated-proteins[127-129] and PAOx-nucleic acids[130] 
conjugates that were previously reported have potential to be modified for hydrogel synthesis using 
physical or covalent crosslinking.  
5.3 Mechanical Properties 
One seldomly mentioned consideration of PAOx hydrogels are their mechanical properties. Most 
water-rich hydrogels are highly elastic but structurally weak and from personal experience are often 
too fragile to test in tensile or tear mode. Yet, the area of tough hydrogels is attracting significant 
attention. Tough hydrogels have been made with other polymer classes including polyacrylamide 
using the strategy of very long chain-lengths between crosslinks[131] and co-gelation of synthetic 
polymers with natural polymers (e.g. alginate) to create interpenetrating networks.[132] PAOx 
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hydrogels that change from gel to liquid with a change in temperature[79] are an example of using 
structure to add dynamic material properties and so it may be possible to create other PAOx structures 
to favourably influence other material/mechanical properties.  
5.4 Hydrogel Characterization 
Characterization methods other than moduli could also be expanded for PAOx hydrogels to better 
understand the network structure and the relationship between hydrogel properties and gelation 
method. One challenge in working with hydrogels is dealing with insoluble materials that are not 
compatible with the regular spectroscopic and spectrometric characterization tools available to the 
synthetic polymer chemist. Solid state NMR spectroscopy has proven useful by the group of 
Schubert[71] for their factor VIII protecting PAOx hydrogels to confirm the crosslinking mechanism. 
They note, however, that the technique is not sensitive enough to quantify the small amount of non-
reacted crosslinker. In the same study they also used an innovative endoscope method in their 
polymerization mixture and show images before and after polymerization showing significant 
heterogeneity and a yellow gel. Other characterization methods such as SAXS have already been 
applied to PAOx hydrogels[79] while other techniques such as XPS and ToF-SIMS currently being 
used for non-hydrogel networks[133] could be adapted for PAOx hydrogels too.  
Another important consideration for PAOx hydrogels when used as biomaterials is their biological 
characterization. It has become an axiom within the field that PAOx is biocompatible, but the long-
term studies (both in vitro and in vivo) are still lacking and will no doubt be completed once products 
approach commercialization. 
5.5 Expanding the Range of Commercially-Available Materials 
Part of the reason why not more research groups have adopted PAOx is perhaps the lack of 
commercial monomers and functional polymers. This shortage is gradually being addressed as 
indicated by Figure 6 and Table 2. The majority of monomers have non-reactive groups in the 2–
position, but the range of polarity is quite broad from highly hydrophilic 2-methyl-2-oxazoline to 
hydrophobic 2-phenyl-oxazoline meaning that a wide range of polymers can be prepared based on 
(co)polymerization of commercial monomers. There is definitely a shortage of monomers with 
reactive groups in the 2-position and of the two listed in Figure 6, namely 2-penta-4-ynyl-2-oxazoline 
and 2-isopropenyl-2-oxazoline, the latter cannot be polymerized to sufficiently high DP due to the 
resonance stabilization caused by the isopropenyl group[134] although modification prior to 
polymerization can circumvent this, e.g. radical polymerization of the C=C group followed by CROP 
of the 2-oxazoline ring[135] or thiol-ene monomer modification followed by CROP.[136] 
The variety in polarity of the commercially-available polymers (Table 2) is less than the monomers 
(confined to methyl, ethyl, propyl side-chains) but the reactive end-group functionality is diverse and 
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includes hydroxyl, alkyne, azide, amine, thiol and piperazine. Despite the diversity in chemistry, none 
of these polymers have the degree of functionality required for synthesizing crosslinked networks. 
Monomers  
 
Figure 6. Commercially available monofunctionalized 2-substituted-oxazoline monomers (at the time 
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-CH3 
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50 ≤1.25 Ultroxa 
-CH3 -N3 10 ≤1.2 Ultroxa 
-CH3 -NH2 5 ≤1.15 Ultroxa 
-CH3 
 
10 ≤1.2 Ultroxa 
-CH3 
 
2 ≤1.2 SA 
5 <1.3 SA 
10 <1.3 SA 
-OH 
 
2 ≤1.3 SA 
5 ≤1.2 SA 
 
-OH 10 ≤1.2 Ultroxa 
 
-SH 
2 ≤1.3 SA 
10 ≤1.3 SA 
 
-CH3 -OH 10 ≤1.2 Ultroxa 
-CH3 -N3 10 ≤1.2 Ultroxa 
 
Table 2. Commercially available PAOx. SA = Sigma Aldrich, Ultroxa = Ultroxa brand distributed 
through Sigma Aldrich, PCI = Polymer Chemistry Innovations Inc. 
6. Conclusions 
The synthesis of poly(2-oxazoline)s has flourished in the last couple of decades, but their use in 
hydrogels is still yet to be fully realized. This is despite the development of ‘clickable’ PAOx and the 
possibilities to readily tailor the hydrophilicity/hydrophobicility of the hydrogels simply by changing 
the monomer selection – a feature not available to many other classes of synthetic polymers. 
Furthermore, there is an axiom within the field that PAOx are biocompatible based on 
overwhelmingly favourable in vivo data for soluble or nanoparticle forms of the polymer and in vitro 
data on networks and coatings. What is lacking, but probably not far off, is a successfully translated 
therapy or device based on PAOx that will undoubtedly encourage more research groups to explore 
this polymer class, including how they can be used to synthesize hydrogels. This, together with the 
growing literature on synthetic methods for the preparation of functional PAOx and the growing 
number of commercial monomers and polymers make PAOx hydrogels a fascinating and promising 





T.D. is supported by the ARC Future Fellowship scheme (FT150100408) and the Australian Nuclear 
Science and Technology Organisation (grant ALNGRA14044). Conflict of interest: RH is one of the 
founders of Avroxa BVBA that commercializes Ultroxa®.  
 
References 
[1] O. Wichterle, D. Lím, Nature 1960, 185, 117-118. 
[2] E. Caló, V. V. Khutoryanskiy, European Polymer Journal 2015, 65, 252-267. 
[3] W. M. Gramlich, I. L. Kim, J. A. Burdick, Biomaterials 2013, 34, 9803-9811. 
[4] M. Malkoch, R. Vestberg, N. Gupta, L. Mespouille, P. Dubois, A. F. Mason, J. L. Hedrick, Q. 
Liao, C. W. Frank, K. Kingsbury, C. J. Hawker, Chemical Communications 2006, 2774-2776. 
[5] M. P. Lutolf, J. L. Lauer-Fields, H. G. Schmoekel, A. T. Metters, F. E. Weber, G. B. Fields, J. 
A. Hubbell, Proceedings of the National Academy of Sciences of the United States of America 2003, 
100, 5413-5418. 
[6] A. Forget, A. Blaeser, F. Miessmer, M. Köpf, D. F. D. Campos, N. H. Voelcker, A. 
Blencowe, H. Fischer, V. P. Shastri, Advanced Healthcare Materials 2017, 6. 
[7] B. L. Farrugia, K. Kempe, U. S. Schubert, R. Hoogenboom, T. R. Dargaville, 
Biomacromolecules 2013, 14, 2724-2732. 
[8] P. S. Lienemann, M. P. Lutolf, M. Ehrbar, Advanced Drug Delivery Reviews 2012, 64, 1078-
1089. 
[9] F. P. W. Melchels, M. A. N. Domingos, T. J. Klein, J. Malda, P. J. Bartolo, D. W. Hutmacher, 
Progress in Polymer Science 2012, 37, 1079-1104. 
[10] S. Yigit, R. Sanyal, A. Sanyal, Chemistry - An Asian Journal 2011, 6, 2648-2659. 
[11] N. Gjorevski, M. P. Lutolf, Nature Protocols 2017, 12, 2263-2274. 
[12] E. Y. Tokuda, C. E. Jones, K. S. Anseth, Integrative Biology (United Kingdom) 2017, 9, 76-
87. 
[13] T. E. Brown, K. S. Anseth, Chemical Society Reviews 2017, 46, 6532-6552. 
[14] C. Yang, F. W. DelRio, H. Ma, A. R. Killaars, L. P. Basta, K. A. Kyburz, K. S. Anseth, 
Proceedings of the National Academy of Sciences of the United States of America 2016, 113, E4439-
E4445. 
[15] C. M. Magin, D. L. Alge, K. S. Anseth, Biomedical Materials (Bristol) 2016, 11. 
[16] S. Zalipsky, J. M. Harris, Introduction to chemistry and biological applications of 
poly(ethylene glycol). In Poly(Ethylene Glycol): Chemistry and Biological Applications, Harris, J. 
M.; Zalipsky, S., Eds. 1997; Vol. 680, pp 1-13. 
[17] R. Hoogenboom, Angewandte Chemie-International Edition 2009, 48, 7978-7994. 
[18] N. Adams, U. S. Schubert, Advanced Drug Delivery Reviews 2007, 59, 1504-1520. 
[19] M. Barz, R. Luxenhofer, R. Zentel, M. J. Vicent, Polymer Chemistry 2011, 2, 1900-1918. 
[20] M. Litt, In American Chemical Society Spring Symposium, San Diego, 2012. 
[21] Y. Chujo, K. Sada, T. Saegusa, Polymer Journal 1993, 25, 599-608. 
[22] Y. Chujo, K. Sada, T. Saegusa, Macromolecules 1993, 26, 6320-6323. 
[23] Y. Chujo, K. Sada, T. Saegusa, Macromolecules 1993, 26, 6315-6319. 
[24] Y. Chujo, K. Sada, R. Nomura, A. Naka, T. Saegusa, Macromolecules 1993, 26, 5611-5614. 
[25] Y. Chujo, K. Sada, A. Naka, R. Nomura, T. Saegusa, Macromolecules 1993, 26, 883-887. 
[26] Y. Chujo, K. Sada, T. Kawasaki, E. Ihara, T. Saegusa, Polymer Bulletin 1993, 31, 311-316. 
[27] Y. Chujo, K. Sada, T. Kawasaki, T. Saegusa, Polymer Journal 1992, 24, 1301-1306. 
[28] Y. Chujo, K. Sada, T. Saegusa, Macromolecules 1990, 23, 2636-2641. 
[29] Y. Chujo, K. Sada, T. Saegusa, Macromolecules 1990, 23, 2693-2697. 
[30] Y. Chujo, K. Sada, K. Matsumoto, T. Saegusa, Macromolecules 1990, 23, 1234-1237. 
[31] Y. Chujo, Y. Yoshifuji, K. Sada, T. Saegusa, Macromolecules 1989, 22, 1074-1077. 
[32] Y. Chujo, K. Sada, K. Matsumoto, T. Saegusa, Polymer Bulletin 1989, 21, 353-356. 
25 
 
[33] T. G. Bassiri, A. Levy, M. Litt, Journal of Polymer Science Part B-Polymer Letters 1967, 5, 
871-879. 
[34] D. A. Tomalia, D. P. Sheetz, Journal of Polymer Science Part A-1-Polymer Chemistry 1966, 
4, 2253-&. 
[35] W. Seeliger, Aufderha.E, W. Diepers, R. Feinauer, R. Nehring, W. Thier, H. Hellmann, 
Angewandte Chemie-International Edition 1966, 5, 875-&. 
[36] T. Kagiya, S. Narisawa, T. Maeda, K. Fukui, Journal of Polymer Science Part B-Polymer 
Letters 1966, 4, 441-&. 
[37] T. D. C. company, May 8 1985. 
[38] M. Glassner, M. Vergaelen, R. Hoogenboom, Polymer International 2018, 67, 32-45. 
[39] F. Wiesbrock, R. Hoogenboom, C. H. Abeln, U. S. Schubert, Macromolecular Rapid 
Communications 2004, 25, 1895-1899. 
[40] R. Hoogenboom, B. D. Monnery Method for the preparation of uniform, high molar mass 
cyclic imino ether polymers. 2016. 
[41] R. Konradi, B. Pidhatika, A. Mühlebach, M. Textor, Langmuir 2008, 24, 613-616. 
[42] N. P. Desai, J. A. Hubbell, Biomaterials 1991, 12, 144-153. 
[43] Y. Chen, B. Pidhatika, T. von Erlach, R. Konradi, M. Textor, H. Hall, T. Lühmann, 
Biointerphases 2014, 9, 031003. 
[44] R. W. Moreadith, T. X. Viegas, M. D. Bentley, J. M. Harris, Z. Fang, K. Yoon, B. Dizman, R. 
Weimer, B. P. Rae, X. Li, C. Rader, D. Standaert, W. Olanow, European Polymer Journal 2017, 88, 
524-552. 
[45] A. M. Kelly, F. Wiesbrock, Macromolecular Rapid Communications 2012, 33, 1632-1647. 
[46] M. Hartlieb, K. Kempe, U. S. Schubert, Journal of Materials Chemistry B 2015, 3, 526-538. 
[47] A. Zahoranová, J. Kronek, Hydrogels Based on Poly(2-oxazoline)s for Pharmaceutical 
Applications. In Handbook of Polymers for Pharmaceutical Technologies, 2015; Vol. 4, pp 231-258. 
[48] M. Hartlieb, D. Pretzel, K. Kempe, C. Fritzsche, R. M. Paulus, M. Gottschaldt, U. S. 
Schubert, Soft Matter 2013, 9, 4693-4704. 
[49] C. Englert, L. Tauhardt, M. Hartlieb, K. Kempe, M. Gottschaldt, U. S. Schubert, 
Biomacromolecules 2014, 15, 1124-1131. 
[50] M. Hartlieb, D. Pretzel, C. Engert, M. Hentschel, K. Kempe, M. Gottschaldt, U. S. Schubert, 
Biomacromolecules 2014, 15, 1970-1978. 
[51] A. D. Lynn, T. R. Kyriakides, S. J. Bryant, Journal of Biomedical Materials Research - Part 
A 2010, 93, 941-953. 




[54] P. Goddard, L. E. Hutchinson, J. Brown, L. J. Brookman, Journal of Controlled Release 
1989, 10, 5-16. 
[55] M. C. Woodle, C. M. Engbers, S. Zalipsky, Bioconjugate Chemistry 1994, 5, 493-496. 
[56] S. Zalipsky, C. B. Hansen, J. M. Oaks, T. M. Allen, Journal of Pharmaceutical Sciences 
1996, 85, 133-137. 
[57] F. C. Gaertner, R. Luxenhofer, B. Blechert, R. Jordan, M. Essler, Journal of Controlled 
Release 2007, 119, 291-300. 
[58] R. Luxenhofer, A. Schulz, C. Roques, S. Li, T. K. Bronich, E. V. Batrakova, R. Jordan, A. V. 
Kabanov, Biomaterials 2010, 31, 4972-4979. 
[59] T. X. Viegas, M. D. Bentley, J. M. Harris, Z. Fang, K. Yoon, B. Dizman, R. Weimer, A. 
Mero, G. Pasut, F. M. Veronese, Bioconjugate Chemistry 2011, 22, 976-986. 
[60] V. M. Gaspar, C. Gonçalves, D. De Melo-Diogo, E. C. Costa, J. A. Queiroz, C. Pichon, F. 
Sousa, I. J. Correia, Journal of Controlled Release 2014, 189, 90-104. 
[61] P. H. Kierstead, H. Okochi, V. J. Venditto, T. C. Chuong, S. Kivimae, J. M. J. Fréchet, F. C. 
Szoka, Journal of Controlled Release 2015, 213, 1-9. 
[62] L. Wyffels, T. Verbrugghen, B. D. Monnery, M. Glassner, S. Stroobants, R. Hoogenboom, S. 
Staelens, Journal of Controlled Release 2016, 235, 63-71. 
26 
 
[63] M. Glassner, L. Palmieri, B. D. Monnery, T. Verbrugghen, S. Deleye, S. Stroobants, S. 
Staelens, L. Wyffels, R. Hoogenboom, Biomacromolecules 2017, 18, 96-102. 
[64] M. A. Boerman, E. Roozen, M. J. Sánchez-Fernández, A. R. Keereweer, R. P. Félix Lanao, J. 
C. M. E. Bender, R. Hoogenboom, S. C. Leeuwenburgh, J. A. Jansen, H. Van Goor, J. C. M. Van 
Hest, Biomacromolecules 2017, 18, 2529-2538. 
[65] O. Sedlacek, B. D. Monnery, J. Mattova, J. Kucka, J. Panek, O. Janouskova, A. Hocherl, B. 
Verbraeken, M. Vergaelen, M. Zadinova, R. Hoogenboom, M. Hruby, Biomaterials 2017, 146, 1-12. 
[66] P. J. M. Bouten, D. Hertsen, M. Vergaelen, B. D. Monnery, M. A. Boerman, H. Goossens, S. 
Catak, J. C. M. Van Hest, V. Van Speybroeck, R. Hoogenboom, Polymer Chemistry 2015, 6, 514-
518. 
[67] D. W. Scharp, P. Marchetti, Advanced Drug Delivery Reviews 2014, 67-68, 35-73. 
[68] B. Guillerm, S. Monge, V. Lapinte, J. J. Robin, Macromolecular Rapid Communications 
2012, 33, 1600-1612. 
[69] A. Zahoranova, Z. Kronekova, M. Zahoran, D. Chorvat, I. Janigova, J. Kronek, Journal of 
Polymer Science Part A-Polymer Chemistry 2016, 54, 1548-1559. 
[70] D. van der Heide, B. Verbraeken, R. Hoogenboom, T. Dargaville, D. Hickey, Biomaterials 
and Tissue Technology 2017, 1, 1-5. 
[71] M. Hartlieb, S. Schubert, K. Kempe, N. Windhab, U. S. Schubert, Journal of Polymer Science 
Part A-Polymer Chemistry 2015, 53, 10-14. 
[72] A. M. Kelly, A. Hecke, B. Wirnsberger, F. Wiesbrock, Macromolecular Rapid 
Communications 2011, 32, 1815-1819. 
[73] T. R. Dargaville, R. Forster, B. L. Farrugia, K. Kempe, L. Voorhaar, U. S. Schubert, R. 
Hoogenboom, Macromolecular Rapid Communications 2012, 33, 1695-1700. 
[74] Y. Chujo, K. Sada, R. Nomura, A. Naka, T. Saegusa, Macromolecules 1993, 26, 5611-5614. 
[75] K. Kempe, A. Vollrath, H. W. Schaefer, T. G. Poehlmann, C. Biskup, R. Hoogenboom, S. 
Hornig, U. S. Schubert, Macromolecular Rapid Communications 2010, 31, 1869-1873. 
[76] T. R. Dargaville, K. Lava, B. Verbraeken, R. Hoogenboom, Macromolecules 2016, 49, 4774-
4783. 
[77] J. N. Haigh, Y. M. Chuang, B. Farrugia, R. Hoogenboom, P. D. Dalton, T. R. Dargaville, 
Macromolecular Rapid Communications 2016, 37, 93-99. 
[78] P. Šrámková, A. Zahoranová, Z. Kroneková, A. Šišková, J. Kronek, Journal of Polymer 
Research 2017, 24. 
[79] T. Lorson, S. Jaksch, M. M. Lübtow, T. Jüngst, J. Groll, T. Lühmann, R. Luxenhofer, 
Biomacromolecules 2017, 18, 2161-2171. 
[80] K. Kempe, Macromolecular Chemistry and Physics 2017, 218. 
[81] I. Sittko, K. Kremser, M. Roth, S. Kuehne, S. Stuhr, J. C. Tiller, Polymer 2015, 64, 122-129. 
[82] S. Luck, R. Schubel, J. Rub, D. Hahn, E. Mathieu, H. Zimmermann, D. Scharnweber, C. 
Werner, S. Pautot, R. Jordan, Biomaterials 2016, 79, 1-14. 
[83] A. Chapiro, Radiation Physics and Chemistry 1995, 46, 159-160. 
[84] T. R. Dargaville, G. A. George, D. J. T. Hill, U. Scheler, A. K. Whittaker, Macromolecules 
2003, 36, 7138-7142. 
[85] S. Zschoche, J. C. Rueda, M. Binner, H. Komber, A. Janke, K. F. Arndt, S. Lehmann, B. Voit, 
Macromolecular Chemistry and Physics 2012, 213, 215-226. 
[86] S. Zschoche, J. Rueda, V. Boyko, F. Krahl, K. F. Arndt, B. Voit, Macromolecular Chemistry 
and Physics 2010, 211, 1035-1042. 
[87] A. E. Ali, A. S. AlArifi, Journal of Applied Polymer Science 2011, 120, 3071-3077. 
[88] O. Sedlacek, J. Kucka, B. D. Monnery, M. Slouf, M. Vetrik, R. Hoogenboom, M. Hruby, 
Polymer Degradation and Stability 2017, 137, 1-10. 
[89] M. M. Lübtow, L. Hahn, M. S. Haider, R. Luxenhofer, Journal of the American Chemical 
Society 2017, 139, 10980-10983. 
[90] L. S. Shenouda, K. A. Adams, M. A. Zoglio, International Journal of Pharmaceutics 1990, 
61, 127-134. 
[91] B. Claeys, A. Vervaeck, C. Vervaet, J. P. Remon, R. Hoogenboom, B. G. De Geest, 
Macromolecular Rapid Communications 2012, 33, 1701-1707. 
27 
 
[92] K. P. Luef, C. Petit, B. Ottersbock, G. Oreski, F. Ehrenfeld, B. Grassl, S. Reynaud, F. 
Wiesbrock, European Polymer Journal 2017, 88, 701-712. 
[93] S. Hendessi, P. Tatar Güner, A. Miko, A. L. Demirel, European Polymer Journal 2017, 88, 
666-678. 
[94] M. Hartlieb, T. Bus, J. Kübel, D. Pretzel, S. Hoeppener, M. N. Leiske, K. Kempe, B. Dietzek, 
U. S. Schubert, Bioconjugate Chemistry 2017, 28, 1229-1235. 
[95] O. Koshkina, D. Westmeier, T. Lang, C. Bantz, A. Hahlbrock, C. Wurth, U. Resch-Genger, 
U. Braun, R. Thiermann, C. Weise, M. Eravci, B. Mohr, H. Schlaad, R. H. Stauber, D. Docter, A. 
Bertin, M. Maskos, Macromolecular Bioscience 2016, 16, 1287-1300. 
[96] H. Bludau, A. E. Czapar, A. S. Pitek, S. Shukla, R. Jordan, N. F. Steinmetz, European 
Polymer Journal 2017, 88, 679-688. 
[97] M. Platen, E. Mathieu, S. Luck, R. Schubel, R. Jordan, S. Pautot, Biomacromolecules 2015, 
16, 1516-1524. 
[98] N. Huettner, T. R. Dargaville, A. Forget, Trends in Biotechnology 2018, accepted. 
[99] M. P. Lutolf, Nature Materials 2009, 8, 451-453. 
[100] B. J. Klotz, D. Gawlitta, A. J. W. P. Rosenberg, J. Malda, F. P. W. Melchels, Trends in 
Biotechnology 2016, 34, 394-407. 
[101] T. R. Dargaville, B. G. Hollier, A. Shokoohmand, R. Hoogenboom, Cell Adhesion and 
Migration 2014, 8, 88-93. 
[102] R. Skalak, C. F. Fox, B. Fung, Preface. In Tissue Engineering, Skalak, R.; Fox, C. F., Eds. 
Alan R Liss Inc.: New York, 1988; pp pp. xix-xxi. 
[103] J. Groll, T. Boland, T. Blunk, J. A. Burdick, D. W. Cho, P. D. Dalton, B. Derby, G. Forgacs, 
Q. Li, V. A. Mironov, L. Moroni, M. Nakamura, W. Shu, S. Takeuchi, G. Vozzi, T. B. F. Woodfield, 
T. Xu, J. J. Yoo, J. Malda, Biofabrication 2016, 8. 
[104] P. Calvert, Z. Liu, Acta Materialia 1998, 46, 2565-2571. 
[105] B. L. Farrugia, T. D. Brown, Z. Upton, D. W. Hutmacher, P. D. Dalton, T. R. Dargaville, 
Biofabrication 2013, 5. 
[106] J. N. Haigh, T. R. Dargaville, P. D. Dalton, Materials Science and Engineering C 2017, 77, 
883-887. 
[107] G. Hochleitner, J. F. Hümmer, R. Luxenhofer, J. Groll, Polymer (United Kingdom) 2014. 
[108] O. I. Kalaoglu-Altan, B. Verbraeken, K. Lava, T. N. Gevrek, R. Sanyal, T. Dargaville, K. De 
Clerck, R. Hoogenboom, A. Sanyal, ACS Macro Letters 2016, 5, 676-681. 
[109] A. Tait, A. L. Fisher, T. Hartland, D. Smart, P. Glynne-Jones, M. Hill, E. J. Swindle, M. 
Grossel, D. E. Davies, Biomaterials 2015, 61, 26-32. 
[110] A. Dworak, A. Utrata-Wesołek, N. Oleszko, W. Wałach, B. Trzebicka, J. Anioł, A. L. Sieroń, 
A. Klama-Baryła, M. Kawecki, Journal of Materials Science: Materials in Medicine 2014, 25, 1149-
1163. 
[111] N. Oleszko, W. Wałach, A. Utrata-Wesołek, A. Kowalczuk, B. Trzebicka, A. Klama-Baryła, 
D. Hoff-Lenczewska, M. Kawecki, M. Lesiak, A. L. Sieroń, A. Dworak, Biomacromolecules 2015, 
16, 2805-2813. 
[112] L. Tan, L. C. Bai, H. K. Zhu, C. Zhang, L. J. Chen, Y. M. Wang, H. Cheradame, Journal of 
Materials Science 2015, 50, 4898-4913. 
[113] C. Zhang, S. T. Liu, L. Tan, H. K. Zhu, Y. M. Wang, Journal of Materials Chemistry B 2015, 
3, 5615-5628. 
[114] H. Zhu, F. Mumtaz, C. Zhang, L. Tan, S. Liu, Y. Zhang, C. Pan, Y. Wang, Applied Surface 
Science 2017, 426, 817-826. 
[115] B. Verbraeken, R. Hoogenboom, Angewandte Chemie - International Edition 2017, 56, 7034-
7036. 
[116] G. Morgese, L. Trachsel, M. Romio, M. Divandari, S. N. Ramakrishna, E. M. Benetti, 
Angewandte Chemie - International Edition 2016, 55, 15583-15588. 
[117] C. H. Chen, Y. Niko, G. Konishi, Rsc Advances 2016, 6, 42962-42970. 
[118] K. Kawamoto, M. Zhong, R. Wang, B. D. Olsen, J. A. Johnson, Macromolecules 2015, 48, 
8980-8988. 
[119] T. Rudolph, S. Crotty, U. S. Schubert, F. H. Schacher, E-Polymers 2015, 15, 227-235. 
28 
 
[120] A. V. Smirnova, T. U. Kirila, M. P. Kurlykin, A. V. Tenkovtsev, A. P. Filippov, International 
Journal of Polymer Analysis and Characterization 2017, 22, 677-684. 
[121] Y. Chujo, K. Sada, T. Kawasaki, T. Saegusa, Polymer Journal 1992, 24, 1301-1306. 
[122] H. M. L. Lambermont-Thijs, M. W. M. Fijten, U. S. Schubert, R. Hoogenboom, Australian 
Journal of Chemistry 2011, 64, 1026-1032. 
[123] M. Hartlieb, T. Floyd, A. B. Cook, C. Sanchez-Cano, S. Catrouillet, J. A. Burns, S. Perrier, 
Polymer Chemistry 2017, 8, 2041-2054. 
[124] M. Schmitz, M. Kuhlmann, O. Reimann, C. P. R. Hackenberger, J. Groll, Biomacromolecules 
2015, 16, 1088-1094. 
[125] H. Jiang, S. Qin, H. Dong, Q. Lei, X. Su, R. Zhuo, Z. Zhong, Soft Matter 2015, 11, 6029-
6036. 
[126] K. Kempe, C. Weber, K. Babiuch, M. Gottschaldt, R. Hoogenboom, U. S. Schubert, 
Biomacromolecules 2011, 12, 2591-2600. 
[127] J. F. Nawroth, J. R. McDaniel, A. Chilkoti, R. Jordan, R. Luxenhofer, Macromolecular 
Bioscience 2016, 16, 322-333. 
[128] A. Mero, Z. Fang, G. Pasut, F. M. Veronese, T. X. Viegas, Journal of Controlled Release 
2012, 159, 353-361. 
[129] A. Mero, G. Pasut, L. D. Via, M. W. M. Fijten, U. S. Schubert, R. Hoogenboom, F. M. 
Veronese, Journal of Controlled Release 2008, 125, 87-95. 
[130] D. Kedracki, M. Chekini, P. Maroni, H. Schlaad, C. Nardin, Biomacromolecules 2014, 15, 
3375-3382. 
[131] S. K. Goswami, C. J. McAdam, L. R. Hanton, S. C. Moratti, Macromolecular Rapid 
Communications 2017, 38. 
[132] J. Y. Sun, X. Zhao, W. R. K. Illeperuma, O. Chaudhuri, K. H. Oh, D. J. Mooney, J. J. 
Vlassak, Z. Suo, Nature 2012, 489, 133-136. 
[133] F. Cavalli, H. Mutlu, S. O. Steinmueller, L. Barner, Polymer Chemistry 2017, 8, 3778-3782. 
[134] C. Weber, T. Neuwirth, K. Kempe, B. Ozkahraman, E. Tamahkar, H. Mert, C. R. Becer, U. S. 
Schubert, Macromolecules 2012, 45, 20-27. 
[135] N. Zhang, S. Huber, A. Schulz, R. Luxenhofer, R. Jordan, Macromolecules 2009, 42, 2215-
2221. 
[136] M. A. Cortez, S. M. Grayson, Macromolecules 2010, 43, 10152-10156. 
 
 
